Pulmonary Arterial Hypertension patient metabolic Phenotype

• Research type

  Research Study

• Full title

  Determine the metabolic phenotype associated with the initiation and progression of pulmonary hypertension.

• IRAS ID

  338397

• Contact name

  Luke Howard

• Contact email

  I.howard@imperial.ac.uk

• Sponsor organisation

  Imperial College London

• Duration of Study in the UK

  2 years, 11 months, 30 days

• Research summary

  Pulmonary arterial hypertension (PAH) is a progressive and destructive disease of the cardiopulmonary vasculature. Despite recent advances in treatment survival remains poor. Initial PAH disease processes are asymptomatic; critically delaying diagnosis and start of treatment.
  This proposal aims to discover, design and develop a breath bio-marker signature in patients with pulmonary hypertension. A bio-marker is anything that can be used as an indicator of a disease or condition. In this study we will be collecting and analysing breath sample with bloods and urine analyse used to confirm breath signature. We will also analyse whole-body metabolic activity pre and post-prandial state by using indirect calorimetry. Pulmonary hypertension progressively switches whole-body metabolic substrate utilisation as the disease progresses. This will influence and potentially correlate with the breath biomarker signature.

• REC name

  North of Scotland Research Ethics Committee 1

• REC reference

  25/NS/0124

• Date of REC Opinion

  2 Dec 2025

• REC opinion

  Further Information Favourable Opinion